Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BGM vs IMMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BGM Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

BGM Overall Winner 6-Pillar Tally: BGM 4 – 1 IMMP (1 Tie) Matrix Metrics: BGM 6 – 4 IMMP

As of Nov 20, 2026, BGM Group Ltd. Class A (BGM) is the stronger overall head-to-head candidate over Immutep Limited (IMMP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas IMMP carries 58.4/100 (HOLD) at $3.11 (7.1x Forward P/E, -409.3% operating margin).

  • Growth vs. Quality Trade-Off: BGM earns the overall head-to-head edge with a stronger Unified Composite Score (59.6/100 HOLD vs. IMMP 58.4/100 HOLD) and 3.69β · 80% Vol risk profile, whereas IMMP leads top-line expansion (+633.5% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGM vs IMMP
BGM NASDAQ Head-to-Head Winner
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25
IMMP NASDAQ
Immutep Limited American Depositary Shares
Pharmaceutical Preparations
$3.11
-9.06% 1D
Market Cap $25.2M
TTM Revenue $20M
Forward P/E 7.1x
Beta / 30D Vol -7.10β · 118% Vol
Unified Composite Score
58.4 / 100 HOLD
Tech 62.0 Fund 38.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.0 · SMA20: $3.27 · SMA50: $2.89

6-Pillar Scorecard Institutional Category Breakdown (BGM 4 – 1 IMMP)

Columns: Metric · BGM · IMMP
1. Valuation Multiples IMMP
Forward P/E N/M 7.1x
Trailing P/E N/M 7.1x
PEG Ratio N/M N/M
EV / Revenue 2.3x 1.3x
2. Growth & Scale BGM
Revenue Growth (YoY) +69.8% +633.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $48M $20M
Market Cap $108.6M $25.2M
3. Profitability & Quality BGM
Gross Margin 16.9% N/A
Operating Margin -23.4% -409.3%
Net Profit Margin -44.2% 0.0%
Return on Equity (ROE) -7.4% -77.3%
4. Balance Sheet & Cash Flow BGM
Cash Generation (TTM) -$9.2M EBITDA -$79M EBITDA
Cash Flow Margin -19.3% EBITDA Mgn N/A
Net Cash / Leverage $59.55 Book/Sh · -7.4% ROE $5.90 Book/Sh · -77.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BGM
OpEx & R&D Intensity 40.3% of Rev ($19M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGM (6) vs IMMP (4)
Institutional Metric BGM IMMP Criterion Row Edge
Market Capitalization
Scale
$108.6M $25.2M Larger Scale BGM
Trailing P/E Ratio
Valuation
N/M 7.1x Lower Multiple IMMP
Forward P/E Ratio
Valuation
N/M 7.1x Lower Multiple IMMP
Revenue Growth (YoY)
Growth
+69.8% +633.5% Higher Growth IMMP
Operating Margin (TTM)
Profitability
-23.4% -409.3% Higher Margin BGM
Net Profit Margin
Profitability
-44.2% 0.0% Higher Margin IMMP
Return on Equity (ROE)
Capital Efficiency
-7.4% -77.3% Higher ROE BGM
52-Week Range Position
Momentum
74% ($0–$11) 56% ($0–$5) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
3.69β · 80% Vol -7.10β · 118% Vol Lower Realized Risk BGM
Unified Institutional Score
Composite Signal
59.6 / 100 (HOLD) 58.4 / 100 (HOLD) Higher Composite BGM
Trailing 12M Revenue (USD)
Operating Scale
$48M $20M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) -$79M EBITDA ($5.90 Book/Sh · -77.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMMP +14.76 pp
BGM: -21.57% · IMMP: -6.81%
3M Horizon BGM +1881.21 pp
BGM: +2673.93% · IMMP: +792.72%
6M Horizon BGM +2335.44 pp
BGM: +2962.79% · IMMP: +627.35%
1Y Horizon IMMP +106.13 pp
BGM: -15.07% · IMMP: +91.06%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs IMMP. Trailing 12-month operating profitability (BGM -23.4% vs IMMP -409.3%) and valuation multiples (BGM N/M vs IMMP 7.1x Forward P/E) are benchmarked directly in Pillar 4 below.

BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M
IMMP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross MarginN/A
Op. Margin-409.3%
ROE / Fwd P/E-77.3% · 7.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IMMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published
IMMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $25.2M market capitalization and -409.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BGM vs IMMP Key Questions & Quantitative Answers

As of Nov 20, 2026, BGM Group Ltd. Class A (BGM) is the stronger overall head-to-head candidate over Immutep Limited (IMMP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas IMMP carries 58.4/100 (HOLD) at $3.11 (7.1x Forward P/E, -409.3% operating margin). Growth vs. Quality Trade-Off: BGM earns the overall head-to-head edge with a stronger Unified Composite Score (59.6/100 HOLD vs. IMMP 58.4/100 HOLD) and 3.69β · 80% Vol risk profile, whereas IMMP leads top-line expansion (+633.5% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

BGM leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with IMMP at +633.5% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (N/A gross margin, -409.3% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $20M for IMMP. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMP.

IMMP screens cheaper on headline valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas IMMP trades at 7.1x Forward P/E, 7.1x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus IMMP (-77.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, IMMP carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.10β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.